The PRECISION study: Prostate evaluation for clinically important disease, sampling using image-guidance or not? (NCT02380027)
BAUS ePoster online library. Kasivisvanathan V. Jun 26, 2018; 211337
Disclosure(s): NIHR Doctoral Fellowship Award European Association of Urology Research Foundation funding
Mr. Veeru Kasivisvanathan
Mr. Veeru Kasivisvanathan
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Introduction: PRECISION aimed to evaluate whether multiparametric MRI and a targeted biopsy only (MRI±TB) was non-inferior to TRUS biopsy in the detection of clinically significant prostate cancer in biopsy naïve men

Patients & Methods: PRECISION was a randomised, non-inferiority trial, carried out in 25 centres in 11 countries. 500 men were randomly allocated to 10-12 core TRUS-biopsy or MRI±TB. Men randomised to MRI±TB underwent MRI followed by targeted biopsy alone (without standard cores) if the PIRADSv2 score was ≥3. Men with a PIRADSv2 score of 1-2 were not offered biopsy. The primary outcome was the proportion of men diagnosed with clinically significant cancer (Gleason grade ≥ 3+4).


Results: One third of men avoided biopsy in the MRI arm (71/252, 28%). Clinically significant cancer was detected in 95 (38%) of 252 men in the MRI±TB arm compared to 64 (26%) of 248 men randomised to TRUS-biopsy (intention-to-treat analysis). Adjusting for centre effects, the absolute difference (MRI±TB versus TRUS-biopsy) in the proportion of men diagnosed with clinically significant prostate cancer was 11.8% (2-sided 95% CI 3.7 to 20.0; p = 0.005). The lower bound of the 95% CI for the difference is greater than -5% therefore MRI±TB was non-inferior to TRUS biopsy. Furthermore, the range of 95% CI was consistent with a claim of superiority of MRI±TB over TRUS-biopsy.

Conclusion: An MRI-targeted approach in biopsy naive men resulted in greater detection of clinically significant disease, less detection of insignificant disease and required fewer biopsies.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings